Home | About Us | Current Issue | Ahead of print | Archives | Search | Instructions | Subscription | Feedback | e-Alerts | Login 
Journal of Indian Association of Pediatric Surgeons
     Journal of Indian Association of Pediatric Surgeons
Official journal of the Indian Association of Pediatric Surgeons         
 Users Online:22 
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size


 
Table of Contents   
LETTER TO THE EDITOR
Year : 2011  |  Volume : 16  |  Issue : 4  |  Page : 173-174
 

Role of propranolol in hemangiomas


Department of Pediatric Surgery, Medical College and Hospital, Kolkata, West Bengal, India

Date of Web Publication31-Oct-2011

Correspondence Address:
Vishal Gajbhiye
136, Sarat Bose Road, Kolkata - 700 029, West Bengal
India
Login to access the Email id


DOI: 10.4103/0971-9261.86892

PMID: 22121324

Get Permissions

 



How to cite this article:
Gajbhiye V, Nath S, Chatterjee S, De A, Ghosh D, Das SK. Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg 2011;16:173-4

How to cite this URL:
Gajbhiye V, Nath S, Chatterjee S, De A, Ghosh D, Das SK. Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg [serial online] 2011 [cited 2014 Sep 20];16:173-4. Available from: http://www.jiaps.com/text.asp?2011/16/4/173/86892


Sir,

Hemangiomas of infancy are common, benign, self-limiting malformations, but a significant percent of these lesions are associated with substantial morbidity and cosmetic disfigurement in infancy and childhood. [1] Current treatment options for problematic hemangiomas include systemic or intralesional corticosteroids, chemotherapeutic agents (vincristine, alfa-interferon), laser, surgery or a combination of these therapies. Unfortunately, each treatment option has limited therapeutic benefit, with its own side-effect and risks. Few case reports have been published where hemangiomas regress rapidly when treated with propranolol at a dose of 2 mg/kg/day. [2],[3]

Propranolol is a nonselective beta-blocker. Its vasoconstrictive property results in reduction in color and size of the hemangioma. Its primary effect, however, appears to be alteration in the progression of angiogenesis in the hemangioma, by decrease in expression of bFGF and VEGF. In addition, propranolol may promote involution of hemangiomas by triggering apoptosis in endothelial cells. [2]

We have performed this prospective study to explore the impact of propranolol on hemangiomas at our center. A total of 40 patients from 3 weeks to 12 months of age with 21 girls and 19 boys were taken in this study. The study period was from February 2010 to July 2011. Detailed clinical examination with history of previous treatment with steroid or other medication was taken. Contraindications for propranolol (e.g., bronchial asthma, hypoglycemia, gastroesophageal reflux, etc.) were recorded and such children were excluded from the study.

An oral dose of 2 mg/kg/day divided into two to three doses was given to each child. [2] Serial photographs were taken at 3-4 weeks intervals during the course of their therapy to record clinical response. The doses were adjusted as the child grows by taking regular body weight of the child. Propranolol was weaned at the end of treatment by reducing the dose to one-half for 1-2 weeks, and then stopped.

Ten of the 40 patients (25%) had complete resolution with no residual disease. Average time taken was 4 months for complete resolution in these cases. Twenty-nine patients (72.5%) showed progressive reduction in size and color of their hemangiomas [Figure 1]. These patients were considered to be partial responders and are on further propranolol therapy. Only one patient (2.5%) had persistent hemangioma growth despite propranolol therapy for 4 months, and was termed nonresponder. In this study, it is also observed that lesions that respond to therapy earlier show complete resolution earlier. There were no report of any side-effects during the study.
Figure 1: (a) Photograph at onset of treatment. (b) Four months posttreatment photograph showing almost complete response

Click here to view


Based on the successful results of our study and few other case reports, propranolol appears to be a valuable and effective treatment option for hemangiomas at therapeutic doses (2 mg/kg/day), and it may revolutionize the treatment of hemangiomas.

 
   References Top

1.Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.  Back to cited text no. 2
    
3.Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: Case report of novel treatment. Laryngoscope 2009;119:2051-4.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1]


This article has been cited by
1 Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review
Ann L. Marqueling,Vikash Oza,Ilona J. Frieden,Katherine B. Puttgen
Pediatric Dermatology. 2013; 30(2): 182
[Pubmed]
2 Propranolol and infantile hemangiomas four years later: A systematic review
Marqueling, A.L. and Oza, V. and Frieden, I.J. and Puttgen, K.B.
Pediatric Dermatology. 2013; 30(2): 182-191
[Pubmed]



 

Top
Print this article  Email this article

    

 
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (568 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed1014    
    Printed50    
    Emailed1    
    PDF Downloaded122    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Contact us | Sitemap | Advertise | What's New | Copyright and Disclaimer 

  2005 - Journal of Indian Association of Pediatric Surgeons | Published by Medknow 

Online since 1st May '05